Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nucala
Pharma
AZ's Fasenra shows comparable efficacy in trial vs. GSK's Nucala
AstraZeneca's Fasenra has demonstrated noninferiority in remission in a head-to-head battle against GSK's Nucala in patients with EGPA.
Kevin Dunleavy
Sep 12, 2023 9:01am
Eisai, Astellas, GSK and more—Fierce Pharma Asia
Jul 21, 2023 8:15am
GSK pulls 2 Nucala batches in Taiwan over glass particle fears
Jul 18, 2023 10:16am
COPD trial data coming soon for Sanofi, Regneron’s Dupixent
Mar 20, 2023 8:34am
AZ's Fasenra takes another hit in battle with GSK's Nucala
Oct 25, 2022 10:10am
AZ uses light humor for a serious subject: eosinophilic asthma
Oct 6, 2022 12:51pm